Annales d'Endocrinologie

Print ISSN
0003-4266
Electronic ISSN
2213-3941
Impact factor
0.583
Publisher
Sciencedirect
URL
http://www.sciencedirect.com/science/journal/00034266
Usage rank
11696
Article count
5287
Free count
2
Free percentage
0.000378286
PDFs via platforms
Sciencedirect from 2004, Ebsconet, Ebscoatoz, and Ebsco

  1. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery.

    Annales d'Endocrinologie 77(3):220 (2016) PMID 27297451

    Treatment of primary aldosteronism (PA) aims at preventing or correcting hypertension, hypokalemia and target organ damage. Patients with lateralized PA and candidates for surgery may be managed by laparoscopic adrenalectomy. Partial adrenalectomy and non-surgical ablation have no proven advanta...
  2. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism.

    Annales d'Endocrinologie 77(3):214 (2016) PMID 27315758

    While the majority of cases of primary aldosteronism (PA) are sporadic, four forms of autosomal-dominant inheritance have been described: familial hyperaldosteronism (FH) types I to IV. FH-I, also called glucocorticoid-remediable aldosteronism, is characterized by early and severe hypertension, ...
  3. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: Confirmatory testing.

    Annales d'Endocrinologie 77(3):202 (2016) PMID 27318644

    Aldosterone/renin ratio (ARR) identifies patients at high or low risk of primary aldosteronism (PA), but sensitivity and especially specificity are suboptimal and confirmatory testing may therefore be necessary, in some but not all patients. In patients with elevated ARR and plasma aldosterone c...
  4. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA?

    Annales d'Endocrinologie 77(3):187 (2016) PMID 27087531

    Depending on the study, the prevalence of primary aldosteronism (PA) in patients with hypertension varies from 6 to 18%. Prevalence is higher in each of the following conditions, any one of which requires screening for PA: severe hypertension (systolic blood pressure [BP]≥180mmHg and/or diastoli...
  5. SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps.

    Annales d'Endocrinologie 77(3):192 (2016) PMID 27177498

    In patients with suspected primary aldosteronism (PA), the first diagnostic step, screening, must have high sensitivity and negative predictive value. The aldosterone-to-renin ratio (ARR) is used because it has higher sensitivity and lower variability than other measures (serum potassium, plasma...
  6. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.

    Annales d'Endocrinologie 77(3):226 (2016) PMID 27315759

    Spironolactone, which is a potent mineralocorticoid receptor antagonist, represents the first line medical treatment of primary aldosteronism (PA). As spironolactone is also an antagonist of the androgen and progesterone receptor, it may present side effects, especially in male patients. In case...
  7. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook.

    Annales d'Endocrinologie 77(3):179 (2016) PMID 27315757

    The French Endocrinology Society (SFE) French Hypertension Society (SFHTA) and Francophone Endocrine Surgery Association (AFCE) have drawn up recommendations for the management of primary aldosteronism (PA), based on an analysis of the literature by 27 experts in 7 work-groups. PA is suspected i...
  8. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: Subtype diagnosis.

    Annales d'Endocrinologie 77(3):208 (2016) PMID 27036860

    To establish the cause of primary aldosteronism (PA), it is essential to distinguish unilateral from bilateral adrenal aldosterone secretion, as adrenalectomy improves aldosterone secretion and controls hypertension and hypokalemia only in the former. Except in the rare cases of type 1 or 3 fami...
  9. Human chorionic gonadotropin: Different glycoforms and biological activity depending on its source of production.

    Annales d'Endocrinologie 77(2):75 (2016) PMID 27177499

    Human chorionic gonadotropin (hCG) is the first hormonal message from the placenta to the mother. It is detectable in maternal blood two days after implantation and behaves like a super LH agonist stimulating progesterone secretion by the corpus luteum. In addition to maintaining the production ...
  10. Prolactinoma and pregnancy: From the wish of conception to lactation.

    Annales d'Endocrinologie 77(2):128 (2016) PMID 27130071

    Prolactinoma is a common cause of infertility in young women and treatment with dopamine agonists (DA) allows restoration of fertility in over 90% of the cases. Both bromocriptine and cabergoline have shown a good safety profile when administered during early pregnancy. In particular, data on ex...
  11. Angiogenic balance (sFlt-1/PlGF) and preeclampsia.

    Annales d'Endocrinologie 77(2):97 (2016) PMID 27130072

    Preeclampsia is a hypertensive disorder of pregnancy associated with important maternal and perinatal mortality and morbidity. Although symptomatic management has improved, there is currently no curative treatment, and only childbirth and delivery of the placenta, usually prematurely, alleviate ...
  12. Hypoparathyroidism and pregnancy.

    Annales d'Endocrinologie 77(2):172 (2016) PMID 27172871

  13. PAPP-A and the IGF system.

    Annales d'Endocrinologie 77(2):90 (2016) PMID 27155776

    Firstly discovered as a placental protein present abundantly in the circulation of pregnant women, pregnancy-associated plasma protein-A (PAPP-A) is widely expressed in multiple tissues. PAPP-A is a metalloproteinase that is able to specifically cleave three insulin-like growth factor binding pr...
  14. Primary aldosteronism and pregnancy.

    Annales d'Endocrinologie 77(2):148 (2016) PMID 27156905

    Hypertension (HT) is a complication of 8% of all pregnancies and 10% of HT cases are due to primary aldosteronism (PA). There is very little data on PA and pregnancy. Given the changes in the renin angiotensin system during pregnancy, the diagnosis of PA is difficult to establish during gestatio...
  15. [Adrenocortical carcinoma and pregnancy].

    Annales d'Endocrinologie 77(2):139 (2016) PMID 27172868

    Adrenocortical carcinoma is a rare cancer with a poor but heterogeneous prognosis. These tumours are more frequently encountered in women, sometimes very young and may be diagnosed in women in their child bearing years or already pregnant. Several clinical data have indicated that the secretion ...
  16. Neuroendocrine control of maternal behavior in non-human and human mammals.

    Annales d'Endocrinologie 77(2):114 (2016) PMID 27130073

    Mammalian parental care is essentially provided by the mother and it occupies most of the reproductive period for female. The synchronization of maternal behavior with parturition and lactation ensures that the mother responds to the needs of the young at the appropriate time. This temporal sync...
  17. Endocrinology of human parturition.

    Annales d'Endocrinologie 77(2):105 (2016) PMID 27155774

    The mechanisms involved in human pregnancy maintenance and parturition are highly complex and involve mother, fetus and placenta. The "final common pathway" to delivery is composed by inflammatory and endocrine interactive paths that tip the balance in favor of coordinated uterine contractility ...
  18. Primary hyperparathyroidism in pregnancy.

    Annales d'Endocrinologie 77(2):169 (2016) PMID 27157105

    Primary hyperparathyroidism (PHPT) is one of the most common endocrine disorders in the general population but is rarely diagnosed during pregnancy. Symptoms of gestational PHPT may be unrecognized, or masked by physiological changes in calcium homeostasis associated with pregnancy. Gestational ...
  19. Evolution of steroids during pregnancy: Maternal, placental and fetal synthesis.

    Annales d'Endocrinologie 77(2):82 (2016) PMID 27155772

    Progesterone, estrogens, androgens and glucocorticoids are involved in pregnancy from implantation to parturition. Their biosynthesis and their metabolism result from complex pathways involving the fetus, the placenta and the mother. The absence of expression of some steroïdogenic enzymes as CYP...
  20. Prolactin and pregnancy in mice and humans.

    Annales d'Endocrinologie 77(2):126 (2016) PMID 27155773